Related Experiment Video

Updated: Jun 14, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Plasma calprotectin predicts mortality in patients with ST segment elevation myocardial infarction treated with

Louise J N Jensen1, Sune Pedersen, Mette Bjerre

  • 1Medical Research Laboratories, Clinical Institute of Medicine and Medical Department of Endocrinology, Aarhus University Hospital, Aarhus, Denmark. ljnoergaard@hotmail.com

Journal of Interventional Cardiology
|March 27, 2010
PubMed

Insights

Plasma calprotectin levels predict mortality in ST segment elevation myocardial infarction (STEMI) patients treated with primary percutaneous coronary intervention (pPCI). Higher levels indicate increased risk, suggesting calprotectin as a prognostic biomarker.

Area of Science:

  • Cardiology
  • Biomarkers
  • Acute Ischemic Heart Disease

Background:

  • ST segment elevation myocardial infarction (STEMI) is a critical condition requiring timely intervention.
  • Primary percutaneous coronary intervention (pPCI) is a standard treatment for STEMI.
  • Identifying reliable prognostic biomarkers is crucial for managing STEMI patients.

Purpose of the Study:

  • To evaluate the predictive value of plasma calprotectin levels for mortality in STEMI patients.
  • To determine if calprotectin levels correlate with adverse outcomes post-pPCI.

Main Methods:

  • Plasma calprotectin levels were measured in 141 STEMI patients treated with pPCI.
  • Levels were compared between STEMI patients and healthy controls.
  • Mortality was assessed over a 12-month follow-up period.
  • Multivariate Cox regression analysis was used to adjust for confounding factors.

Main Results:

  • STEMI patients had significantly higher plasma calprotectin levels than healthy controls (P < 0.001).
  • Elevated calprotectin levels were associated with increased 12-month mortality (209 microg/L vs. 174 microg/L, P < 0.001).
  • Each 10 microg/L increase in calprotectin raised mortality risk by 1.26 (P = 0.001).
  • Calprotectin levels >177 microg/L conferred an 11.11-fold increased mortality risk (P = 0.004).

Conclusions:

  • Plasma calprotectin levels at admission are a significant predictor of 12-month mortality in STEMI patients treated with pPCI.
  • Calprotectin may serve as a novel prognostic biomarker in acute ischemic heart disease.
  • This finding supports the potential clinical utility of calprotectin in risk stratification for STEMI.
Abstract

More Related Videos

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia07:25

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

Related Concept Videos

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...